Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

What Are Mitochondrial-Derived Peptides? MOTS-c and Humanin Explained

Conceptual illustration of mitochondrial DNA beside two distinct short peptide chains representing MOTS-c and humanin.

Mitochondrial-derived peptides (MDPs) are short signaling peptides encoded by small open reading frames (sORFs) in mitochondrial DNA. They are distinct from the 13 oxidative-phosphorylation subunits that mtDNA also encodes. Two representative members are MOTS-c, a 16-amino-acid peptide encoded within the 12S ribosomal RNA gene, and humanin, commonly described as a 24-amino-acid peptide encoded within the 16S ribosomal RNA gene.[1] MOTS-c is studied primarily for metabolic regulation and insulin sensitivity;[2] humanin is studied for cell-survival signaling, neuroprotection, and interactions with proteins involved in apoptosis.[3]

What Counts as a Mitochondrial-Derived Peptide

Human mtDNA contains 16,569 nucleotides and 37 conventionally annotated genes: 13 encoding oxidative-phosphorylation subunits, two encoding ribosomal RNAs, and 22 encoding transfer RNAs. MDP research identifies additional peptide-coding information within this compact genome. The recognized groups include humanin, MOTS-c, and six small humanin-like peptides, SHLP1–6.[1]

These peptides come from specific regions rather than from the breakdown of larger respiratory-chain proteins. The MOTS-c sORF lies within MT-RNR1, the mitochondrial 12S rRNA gene. Humanin and the SHLP sequences lie within the 16S rRNA region, MT-RNR2. A region normally discussed as a source of ribosomal RNA can therefore also contain a short peptide-coding frame.[1] This overlapping genetic organization explains why the word “derived” refers to mitochondrial genetic origin, not necessarily to where the finished peptide is made or acts.

Most mitochondrial proteins follow a different route: nuclear genes encode them, they are synthesized in the cytosol, and they are then imported into the appropriate mitochondrial compartments.[4] MDPs instead originate from mtDNA sORFs. MOTS-c provides a specific example in which mitochondrial genetic origin is combined with cytosolic translation: its sequence requires the standard genetic code to produce the reported peptide.[2] That mechanism should not be generalized into a single production or transport pathway for every MDP.

Humanin adds a further distinction. The nuclear genome contains related sequences called MTRNR2L paralogs, derived from mitochondrial DNA segments. Their expression status is unresolved in the cited account.[3] Their presence is not equivalent to demonstrating that a particular humanin measurement came from a nuclear gene, nor does it make them interchangeable with ordinary nuclear-encoded proteins imported into mitochondria.

How mtDNA-Encoded Short Peptides Reach the Cytosol and Circulation

For MOTS-c, the key proposed export step concerns RNA rather than a completed peptide. Its 51-base-pair sORF produces the reported 16-residue sequence under the standard genetic code, whereas use of the mitochondrial code would introduce incompatible stop signals. The discovery study therefore concluded that translation occurs in the cytoplasm and proposed export of a polyadenylated transcript from mitochondria.[2] This does not establish a finished MOTS-c peptide crossing mitochondrial membranes.

Humanin can be released from cells: after humanin cDNA was introduced into cultured cells, the resulting peptide appeared in the culture medium.[5] This demonstrates secretion in that experimental setting, not the complete pathway from mitochondrial transcription to bloodstream delivery in humans.

MDPs are discussed as local, paracrine signals and as endocrine signals acting at a distance.[1] Those descriptions concern the scale of signaling. They do not identify every molecular step of release. The proposed MOTS-c RNA-export mechanism and the humanin cell-culture secretion experiment answer different parts of the transport question; neither supplies a common, fully traced route for both peptides.

MOTS-c: A 16-Amino-Acid Metabolic Peptide

Conceptual short peptide chain alongside a cutaway skeletal-muscle fiber containing mitochondria.

MOTS-c was reported in 2015 as a peptide linking mitochondrial genetic information to metabolic regulation.[2] Its chemical identity differs substantially from humanin despite their shared classification.

Property MOTS-c Humanin, 24-residue form
Sequence MRWQEMGYIFYPRKLR MAPRGFSCLLLLTSEIDLPVKRRA
Length 16 amino acids 24 amino acids
Molecular formula C101H152N28O22S2 C119H204N34O32S2
Reported molecular mass 2174.62 Da 2687.27 Da
Reported isoelectric point 10.63 9.12
Reported net charge at pH 7.0 +2.83 +1.22
mtDNA region MT-RNR1, 12S rRNA MT-RNR2, 16S rRNA

Sequences, masses, isoelectric points, and charge values are reported in the MDP review; the molecular formulas are listed in the respective peptide entries.[1][3][6] These identity descriptors do not specify a particular preparation’s formulation or purity.

MOTS-c contains no cysteine in its reported sequence and therefore has no cysteine pair available for an intramolecular disulfide bond. Its arginine and lysine residues are consistent with its reported positive charge. Sequence conservation is another notable feature: the discovery study found particularly strong conservation among the first 11 residues across 14 species, while the review identifies the central MGYIF segment as highly conserved.[2][1] These are sequence features, not evidence for a single fixed three-dimensional conformation.

In cultured-cell experiments, MOTS-c inhibited the methionine-folate cycle and associated de novo purine synthesis. AICAR, an intermediate linked to AMPK activation, accumulated more than 20-fold in the reported MOTS-c-expressing cell model. AMPK and Akt phosphorylation also increased. Reducing AMPK expression or inhibiting AMPK diminished the glycolytic response, supporting a role for that signaling pathway rather than merely showing that two measurements changed together.[2]

In mouse experiments, MOTS-c improved insulin sensitivity and prevented diet-induced obesity under the tested conditions. Clamp measurements showed an approximately 30% increase in the glucose infusion rate needed to maintain the experimental glucose target, alongside improved insulin-stimulated glucose disposal and comparable hepatic glucose production between groups. The study also reported protection against age-related insulin resistance.[2] These findings concern metabolic responses in mice, not demonstrated treatment effects in people.

Humanin: A 24-Amino-Acid Cytoprotective Peptide

Schematic short peptide with a three-turn helical segment beside separate neuronal and endothelial cell illustrations.

The chemical comparison above uses the commonly described 24-residue humanin sequence. A three-turn alpha-helical structure has been reported. The cited account also describes shorter mitochondrial forms but inconsistently gives their length as 20 or 21 residues; those shorter forms should not be assigned a settled identity from that account.[3]

Humanin can participate in signaling outside and inside cells. Published extracellular interactions include a receptor complex comprising gp130, WSX1, and CNTFR, as well as formyl peptide receptor 2. Reported intracellular interaction partners include BAX, tBID, IGFBP3, and TRIM11.[3] This makes “cytoprotective” a description of experimentally observed activity, not a claim that the peptide universally benefits every cell or tissue.

In the original neuronal-cell work, humanin cDNA expression prevented cell death induced by several familial Alzheimer’s disease genes and by amyloid-beta. It did not prevent death caused by Q79 or superoxide dismutase-1 mutants, and the rescue depended on humanin’s primary structure.[5] The selective response matters: protection against particular experimental insults does not establish a general ability to prevent neurodegeneration.

A separate cultured-endothelial-cell experiment examined oxidative stress and apoptosis. At the tested in vitro concentration, humanin pretreatment reduced oxidized-LDL-induced reactive oxygen species and apoptosis by approximately half, with a smaller reduction in ceramide formation.[7] These are cellular endpoints, not measurements of cardiovascular outcomes in patients.

Humanin also has a metabolic research history. Rat clamp experiments found improved insulin sensitivity after central humanin exposure; potent humanin derivatives delivered peripherally reproduced insulin-sensitizing effects. A potent analog also lowered blood glucose in Zucker diabetic fatty rats.[8] Native humanin and its derivatives must remain distinguishable when describing these findings.

For example, HNG substitutes glycine for serine at position 14, while HNGF6A additionally substitutes alanine for phenylalanine at position 6. Their activities can differ from native humanin depending on the assay. Experimental reports of tumor promotion and interference with chemotherapy also show why cell-survival signaling cannot automatically be equated with a desirable effect in every biological context.[3]

Comparing the Evidence: Cells, Animals, and Humans

Member Cell and in vitro work Animal work Human observational evidence
MOTS-c Metabolic-pathway and signaling experiments Insulin-sensitivity and obesity experiments in mice Detection in human plasma by MOTS-c-specific ELISA.[2]
Humanin Neuronal-cell protection and endothelial-cell stress models Insulin-action experiments in rats, including studies of derivatives Circulating levels reported to decline with age; immunostaining detected humanin in the endothelial layer of human internal mammary arteries, atherosclerotic coronary arteries, and saphenous vein sections.[8][7]

These human findings are observational; none of the supplied sources reports a human intervention outcome for either peptide.[2][8][7]

The experimental endpoint determines what can be concluded. Changes in cell signaling help explain a possible mechanism. Glucose-clamp measurements test insulin action in an intact animal. A circulating concentration or tissue stain establishes a different kind of observation: it does not measure the effect of administering a peptide. Likewise, an analog’s experimental activity cannot simply be assigned to the native sequence. Keeping molecule, model, and endpoint together is more informative than treating all MDP findings as one category of evidence.

Related research: How Does MOTS-c Affect AMPK Signaling?; Retatrutide + MOTS-c Stack: Evidence Map (Not a Protocol); SS-31 vs MOTS-c: Two Different Approaches to Mitochondrial Research; What Is MOTS-c.

Research Use Only Disclaimer. This article is for laboratory research and analytical education. It is not a validated experimental protocol or medical or veterinary advice. The research materials discussed are not for administration to humans or animals; no dosing, personal preparation, treatment, or purchasing guidance is provided.

References

  1. Mitochondrial-derived peptides: Antidiabetic functions and evolutionary perspectives — Kal et al., 2024
  2. The Mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance — Lee et al., 2015
  3. Humanin — Wikipedia
  4. Regulation of cellular proteostasis via mitochondrial protein import — Nguyen and Li, 2026, abstract
  5. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta — Hashimoto et al., 2001, abstract
  6. MOTS-c — Wikipedia
  7. Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress — Bachar et al., 2010, abstract
  8. Humanin: a novel central regulator of peripheral insulin action — Muzumdar et al., 2009, abstract